Astatine-211: its possible applications in cancer therapy.
The cyclotron-produced radiohalogen, 211At, is eminently suitable as a possible therapeutic radionuclide. It decays by the emission of 6.8 MeV mean energy alpha-particles, which from a radiobiological viewpoint are of near optimal therapeutic LET. This paper reviews developments in the possible application of [211At]astato-labelled molecules as potential anti-tumour agents. Additionally, radio-dosimetric evidence is presented, and its implications for human cancer therapy are discussed.
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D001246:Astatine / Q000627:therapeutic use*; D006801:Humans; D008545:Melanoma / Q000532:radiotherapy; D009285:Naphthoquinones / Q000627:therapeutic use; D009369:Neoplasms / Q000532:radiotherapy*; D009694:Nucleic Acid Precursors / Q000627:therapeutic use; D011879:Radiotherapy Dosage
D000911:Antibodies, Monoclonal; D009285:Naphthoquinones; D009694:Nucleic Acid Precursors; D001246:Astatine